ReviewMolecules (Basel, Switzerland)2014
Invasive fungal infections in the ICU: how to approach, how to treat.
Review in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Transcriptomic meta-analysis to identify potential antifungal targets in Candida albicans.BMC microbiology · 2024Pooled it
- Choosing the Right Antifungal Agent in ICU Patients.Advances in therapy · 2019Pooled it
- Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.The Cochrane database of systematic reviews · 2015Pooled it
- Early Bedside Risk Stratification in ICU Patients with Suspected Invasive Pulmonary Aspergillosis: A Minimalist Clinical Decision Support Model.Journal of fungi (Basel, Switzerland) · 2026Article
- Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study.Pharmaceutics · 2026Article
- Review
- Contrasting Biofilm-Modulating Effects of Polymeric Quaternary Ammonium Compounds on the Pathogenic YeastsACS omega · 2026Article
- Clinical Characteristics, Microbiological Sources, and Outcomes ofJournal of clinical medicine · 2026Article
- The Complement System in the Setting of Critical Illness-A Narrative Review.Biomolecules · 2026Review
- Pogostone disrupts key virulence traits of Candida albicans: hyphal inhibition and biofilm suppression.BMC microbiology · 2026Article
- Characterization and Phenolic Profiling of AnticandidalACS omega · 2025Article
- Identification of chicken-derived antibodies targeting the Candida albicans Als3 protein.Applied microbiology and biotechnology · 2025Article
- Antimicrobial Activity of the Peptide C14R Against Ab Initio Growing and Preformed Biofilms ofBiomolecules · 2025Article
- Fungal Infections in Kidney Transplant Recipients: A Comprehensive Narrative Review.Microorganisms · 2025Review
- Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistantCurrent medical mycology · 2025Article
- Plumieride as a novel anti-fungal and anti-inflammatory iridoid against superficial candidiasis in mice.BMC complementary medicine and therapies · 2024Article
- Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit.Mycopathologia · 2024Article
- Amphotericin B in the Era of New Antifungals: Where Will It Stand?Journal of fungi (Basel, Switzerland) · 2024Review
- Exploring the role of candidalysin in the pathogenicity ofAmerican journal of translational research · 2024Article
- Antifungal and antibiofilm effects of probioticFrontiers in cellular and infection microbiology · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections are a growing problem in critically ill patients and are associated with increased morbidity and mortality. Most of them are due to Candida species, especially Candida albicans. Invasive candidiasis includes candidaemia, disseminated candidiasis with deep organ involvement and chronic disseminated candidiasis. During the last decades rare pathogenic fungi, such as Aspergillus species, Zygomycetes, Fusarium species and Scedosporium have also emerged. Timely diagnosis and proper treatment are of paramount importance for a favorable outcome. Besides blood cultures, several laboratory tests have been developed in the hope of facilitating an earlier detection of infection. The antifungal armamentarium has also been expanded allowing a treatment choice tailored to individual patients' needs. The physician can choose among the old class of polyenes, the older and newer azoles and the echinocandins. Factors related to patient's clinical situation and present co-morbidities, local epidemiology data and purpose of treatment (prophylactic, pre-emptive, empiric or definitive) should be taken into account for the appropriate choice of antifungal agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.